CN106360742A - 一种用于肥胖或减脂手术患者的营养食品组合物 - Google Patents
一种用于肥胖或减脂手术患者的营养食品组合物 Download PDFInfo
- Publication number
- CN106360742A CN106360742A CN201610965457.5A CN201610965457A CN106360742A CN 106360742 A CN106360742 A CN 106360742A CN 201610965457 A CN201610965457 A CN 201610965457A CN 106360742 A CN106360742 A CN 106360742A
- Authority
- CN
- China
- Prior art keywords
- parts
- fat
- food composition
- microencapsulation
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 235000008935 nutritious Nutrition 0.000 title claims abstract description 42
- 235000019197 fats Nutrition 0.000 claims abstract description 62
- 239000000843 powder Substances 0.000 claims abstract description 27
- 102000014171 Milk Proteins Human genes 0.000 claims abstract description 12
- 108010011756 Milk Proteins Proteins 0.000 claims abstract description 12
- 235000021239 milk protein Nutrition 0.000 claims abstract description 12
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 12
- 229920002261 Corn starch Polymers 0.000 claims abstract description 9
- 239000008120 corn starch Substances 0.000 claims abstract description 9
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims description 34
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 27
- 235000018102 proteins Nutrition 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 230000001603 reducing effect Effects 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 18
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 18
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 10
- 229960000304 folic acid Drugs 0.000 claims description 10
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- 229940108325 retinyl palmitate Drugs 0.000 claims description 10
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 10
- 239000011769 retinyl palmitate Substances 0.000 claims description 10
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 claims description 10
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 10
- 229940021056 vitamin d3 Drugs 0.000 claims description 10
- 239000011665 D-biotin Substances 0.000 claims description 9
- 235000000638 D-biotin Nutrition 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 9
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 9
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 9
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 9
- 240000003768 Solanum lycopersicum Species 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 claims description 9
- 239000011609 ammonium molybdate Substances 0.000 claims description 9
- 235000018660 ammonium molybdate Nutrition 0.000 claims description 9
- 229940010552 ammonium molybdate Drugs 0.000 claims description 9
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 9
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 9
- FWBOFUGDKHMVPI-UHFFFAOYSA-K dicopper;2-oxidopropane-1,2,3-tricarboxylate Chemical compound [Cu+2].[Cu+2].[O-]C(=O)CC([O-])(C([O-])=O)CC([O-])=O FWBOFUGDKHMVPI-UHFFFAOYSA-K 0.000 claims description 9
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 9
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 9
- 239000011565 manganese chloride Substances 0.000 claims description 9
- 235000002867 manganese chloride Nutrition 0.000 claims description 9
- 229940099607 manganese chloride Drugs 0.000 claims description 9
- 235000001968 nicotinic acid Nutrition 0.000 claims description 9
- 229960003512 nicotinic acid Drugs 0.000 claims description 9
- 239000011664 nicotinic acid Substances 0.000 claims description 9
- 235000008390 olive oil Nutrition 0.000 claims description 9
- 239000004006 olive oil Substances 0.000 claims description 9
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims description 9
- 235000019175 phylloquinone Nutrition 0.000 claims description 9
- 239000011772 phylloquinone Substances 0.000 claims description 9
- 229960001898 phytomenadione Drugs 0.000 claims description 9
- 235000007715 potassium iodide Nutrition 0.000 claims description 9
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 9
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 9
- 229960001327 pyridoxal phosphate Drugs 0.000 claims description 9
- 229950001574 riboflavin phosphate Drugs 0.000 claims description 9
- 239000001509 sodium citrate Substances 0.000 claims description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 9
- 239000011781 sodium selenite Substances 0.000 claims description 9
- 235000015921 sodium selenite Nutrition 0.000 claims description 9
- 229960001471 sodium selenite Drugs 0.000 claims description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 9
- 235000005282 vitamin D3 Nutrition 0.000 claims description 9
- 239000011647 vitamin D3 Substances 0.000 claims description 9
- IELOKBJPULMYRW-IKTKBOKFSA-N 4-oxo-4-[[(2S)-2,5,7,8-tetramethyl-2-[(4S,8S)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl]oxy]butanoic acid Chemical compound CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OC(CCC(O)=O)=O IELOKBJPULMYRW-IKTKBOKFSA-N 0.000 claims description 8
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 8
- 239000004227 calcium gluconate Substances 0.000 claims description 8
- 235000013927 calcium gluconate Nutrition 0.000 claims description 8
- 229960004494 calcium gluconate Drugs 0.000 claims description 8
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 8
- 239000011787 zinc oxide Substances 0.000 claims description 8
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 claims description 7
- 239000004224 potassium gluconate Substances 0.000 claims description 7
- 235000013926 potassium gluconate Nutrition 0.000 claims description 7
- 229960003189 potassium gluconate Drugs 0.000 claims description 7
- 235000019202 steviosides Nutrition 0.000 claims description 7
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 6
- 229940013618 stevioside Drugs 0.000 claims description 6
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 6
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 claims 2
- 210000004369 blood Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 240000005979 Hordeum vulgare Species 0.000 abstract description 5
- 235000007340 Hordeum vulgare Nutrition 0.000 abstract description 5
- 230000037396 body weight Effects 0.000 abstract description 3
- 235000013312 flour Nutrition 0.000 abstract 3
- 108010084695 Pea Proteins Proteins 0.000 abstract 1
- 235000019483 Peanut oil Nutrition 0.000 abstract 1
- 239000003094 microcapsule Substances 0.000 abstract 1
- 235000019702 pea protein Nutrition 0.000 abstract 1
- 239000000312 peanut oil Substances 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 description 39
- 235000020824 obesity Nutrition 0.000 description 39
- 230000006870 function Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- 235000016709 nutrition Nutrition 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000035764 nutrition Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 206010033307 Overweight Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- -1 DAA Chemical compound 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- 241000998584 Nuda Species 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 235000021196 dietary intervention Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- 206010002641 Anorchism Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- MJHZPNZKADTPDP-UHFFFAOYSA-N (4-formyl-5-hydroxy-6-methylpyridin-1-ium-3-yl)methyl-hydroxyphosphinate Chemical compound CC1=NC=C(CP(O)(O)=O)C(C=O)=C1O MJHZPNZKADTPDP-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010068783 Alstroem syndrome Diseases 0.000 description 1
- 201000005932 Alstrom Syndrome Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000018548 hypothalamic dysfunction Diseases 0.000 description 1
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009593 intrauterine fetal growth Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明涉及一种用于肥胖或减脂手术患者的营养食品组合物,即一种全营养配方食品,它含有牛奶蛋白、脱脂乳粉、豌豆蛋白、青稞粉、水解玉米淀粉、膳食纤维、微囊化花生油、青稞粉、HMB‑Ca等多种组分。本发明营养食品组合物具有血脂、体重指数等指标明显改善作用,且青稞粉和HMB‑Ca具有显著的协同效果,因此,本发明营养食品组合物具有非常好的应用前景。
Description
【技术领域】
本发明属于特殊医学用途食品技术领域。更具体地,本发明涉及一种用于肥胖或减脂手术患者的营养食品组合物,即一种全营养配方食品。
【背景技术】
肥胖是能量摄入超过能量消耗,导致体内脂肪积聚过多达到危害健康程度的一种由多因素引起的慢性代谢性疾病。肥胖是糖尿病、高血压、高血脂、冠心病、脑卒中、乳腺癌等多种疾病发生的危险因素。
人体主要由60%水分、17%蛋白质、5%灰分以及18%以甘油三苷酯形式存在的脂肪组成。肥胖患者的一般特点是体内脂肪细胞体积和数量增加,体脂占体重的百分比异常增加,并在局部过多沉积。
目前,将肥胖分为单纯性肥胖和继发性肥胖两种。
一种是单纯性肥胖,它是指没有内分泌疾病或找不出其它引起肥胖的特殊病因,仅由于能量摄入和消耗之间不平衡引起的肥胖症。单纯性肥胖占总人群的95%以上,肥胖儿童中90%以上属于单纯性肥胖。此外,父母肥胖等遗传因素也是单纯性肥胖发生的一个重要方面,社会心理学研究还发现肥胖与情绪紧张、忧郁等心理因素也可能相关。单纯性肥胖可发生在任何年龄阶段,婴幼儿时期肥胖已被认为是成年肥胖的危险因素,最新研究发现胎儿宫内生长迟缓、低出生体重也可导致成年后肥胖,原因与其出生后早期追赶生长过程中体重增加过速有关。
另一种是继发性肥胖,继发性肥胖主要是指继发于神经-内分泌-代谢紊乱基础上的肥胖或其他遗传疾病导致的肥胖。如各种原因引起的下丘脑综合征包括遗传性代谢缺陷、炎症、创伤、出血、肿瘤等均可能引起肥胖;垂体前叶功能衰减、垂体瘤等垂体病变;原发或继发于丘脑-垂体-甲状腺病变者,由于代谢率低下,脂肪动员相对较少,从而引起肥胖,常伴有黏液性水肿;各种原因引起体内皮质醇增多,形成典型的向心性肥胖,表现为面部、颈部、躯干部脂肪沉积增多,四肢脂肪组织分布相对减少;胰岛病变,胰岛肿瘤、功能性自发性低血糖症,反复发作的低血糖,迫使病人通过增加进食来缓解症状,食欲亢进加之高胰岛素血症使合成代谢增加导致肥胖,脂肪分布呈普遍性,皮下脂肪丰满;女性更年期综合症及少数多囊卵巢综合征、男性无睾或类无睾综合征,以及一些与遗传相关的综合征均可引起肥胖;某些遗传疾病,如Laurence-Moon-Bardet-Biedl综合征、Alstrom综合征、Prader-Willi综合征及Down综合征等引起肥胖。
据WHO的调查显示,无论是在发达国家还是发展中国家,肥胖患病率正以惊人的速度在全球范围内增长。中国在1986年全国儿童单纯性肥胖的检出率仅0.91%,而根据2002年中国居民营养与健康调查结果显示1岁-6岁组儿童肥胖率已经升至2.0%、超重率3.4%,7岁-17岁人群肥胖率2.1%、超重率高至4.5%,而18岁以上人群肥胖率为7.1%、超重率22.8%,超重和肥胖人群已经接近总人口的1/4,成为影响居民健康的重要疾病。从整体来看,我国人群超重和肥胖流行的发展阶段晚于欧美发达国家。根据世界卫生组织超重和肥胖的分类标准来衡量,我国成人超重、肥胖之比为8:1,而欧美国家比例已经达到2:1,甚至接近1:1,这意味着如果对超重者不加以干预,我国肥胖病发病的潜在上升危险性很大。
肥胖可诱发引起相关的疾病,例如心血管疾病(高血压、高血脂、冠心病)、糖尿病等,严重者可引起猝死。
目前,肥胖、减脂手术全营养配方食品(CN 104187709 A),肥胖、减脂手术非全营养配方食品(CN 104855967 A),一种肥胖、减脂手术用全营养乳剂型配方食品及其制备方法(201510606182.1),均采用传统药食同源中药材和其他基础营养素搭配制备产品,可作为单一营养来源补充肥胖人群的营养需求,但忽略了肥胖人群、尤其是减脂手术的手术期患者可能会服用药品辅助治疗,而产品中若添加具有生物活性成分的传统中药材,可能会影响到肥胖患者的减肥效果或使减脂手术预后不佳,并且产品具有中药材特有的苦涩味,不适用于患者长期食用。
【发明内容】
[要解决的技术问题]
本发明的目的是提供一种用于肥胖或减脂手术患者的营养食品组合物,即一种全营养配方食品。
[技术方案]
本发明是通过下述技术方案实现的。
本发明涉及一种用于肥胖或减脂手术患者的营养食品组合物。
针对现有技术中存在的一些技术缺陷,为了减少中药材中活性成分对患者不利影响,本发明使用的原料均采用食品级原料,其中维生素和矿物质化合物符合营养强化剂的要求,特别添加西藏精制青稞粉。此外,对于肥胖的营养治疗措施首先是控制总能量的摄入,即饮食供给的能量低于人体的实际消耗,使人体造成能量的负平衡,促使长期超标的能量被代谢掉,在此过程中易造成肌肉的流失,因此本发明另一个创新点是采用高蛋白低脂配方。此外还添加了β-羟基-β-甲基丁酸钙(HMB-Ca)成分,在减脂的同时,通过代谢调控可减少患者的肌肉损耗量。通过产品配方优化、调配,产品口感适合肥胖患者长期食用。
该营养食品组合物组成如下:以重量份计
牛奶蛋白3.30~3.50份;脱脂乳粉2.53~2.73份;豌豆蛋白3.08~3.28份;青稞粉1.90~2.10份;水解玉米淀粉5.90~6.10份;膳食纤维3.65~3.85份;微囊化花生油0.55~0.65份;微囊化橄榄油0.55~0.65份;微囊化番茄籽油0.16~0.24份;HMB-Ca 0.22~0.28份;食品用香精0.16~0.24份;葡萄糖酸钙0.16~0.20份;甜菊糖苷0.11~0.13份;葡萄糖酸钾0.10~0.12份;柠檬酸钠0.09~0.11份;硫酸镁0.075~0.085份;L-抗坏血酸-6-棕榈酸盐(3.2~3.4)×10-2份;dl-α-琥珀酸生育酚(3.5~3.7)×10-3份;烟酸(8.3~8.5)×10-3份;D-泛酸钙(2.4~2.6)×10-3份;甘氨酸亚铁(4.4~4.6)×10-3份;氧化锌(2.7~2.9)×10-3份;棕榈酸视黄酯(3.0~3.2)×10-4份;柠檬酸铜(3.8~4.0)×10-4份;硝酸硫胺素(8.3~8.5)×10-4份;核黄素-5'-磷酸钠(5.5~5.7)×10-4份;5'-磷酸吡哆醛(5.5~5.7)×10-4份;蝶酰谷氨酸(0.9~1.1)×10-4份;碘化钾(6.1~6.3)×10-5份;钼酸铵(1.3~1.5)×10-5份;亚硒酸钠(1.15~1.35)×10-5份;盐酸氰钴胺(1.70~1.9)×10-6份;D-生物素(3.9~4.1)×10-6份;氯化锰(1.1~1.3)×10-6份;胆钙化醇(2.0~2.2)×10-6份;植物甲萘醌(4.0~6.0)×10-6份。
其中,HMB-Ca是以次氯酸钠、二丙酮醇、盐酸、乙酸乙酯、乙醇、氢氧化钙为主要原料,经氧化合成、酸化、萃取、中和反应、离心、干燥等步骤生产而成的,是国家卫生部批准的新食品原料,使用范围包括运动营养食品、特殊医学用途配方食品等。HMB在肌肉组织的蛋白质合成中起重要作用,可使人体脂肪减少,减少肌肉蛋白质消耗。HMB-Ca也是一种很强的免疫受激剂,能增强人体免疫功能,降低血胆固醇的作用,可减少疾病的发生。它在本发明营养食品组合物中的主要作用是促进肥胖或减脂手术患者减脂,并通过代谢调控可减少患者的肌肉损耗量。
L-抗坏血酸-6-棕榈酸盐又名抗坏血酸棕榈酸酯,是维生素C的化合物来源之一,被世界卫生组织(WHO)食品添加剂委员会评定为具有营养性、无毒、高效、使用安全的食品添加剂,是我国唯一可用于婴幼儿食品的抗氧化剂,本品用于食品可起到抗氧化、营养强化等功效。它在本发明营养食品组合物中的主要作用是改善脂肪和类脂,特别是胆固醇的代谢,预防心血管疾病发生。
dl-α-琥珀酸生育酚是一种具有3,4-二氢-2,5,7,8-四甲基-2-(4,8,12-三甲基十三烷基)-6-色满醇化学结构的化合物,它在本发明营养食品组合物中的主要作用是改善脂质代谢,预防冠心病、动脉粥样硬化。
D-泛酸钙(维生素B5)是一种具有D-(+)-N-(2,4-二羟基-3,3-二甲基丁酰)-β-氨基丙酸钙化学式的化合物,它在本发明营养食品组合物中的主要作用是增强免疫力,辅助糖类,脂肪及蛋白质产生人体能量。加速伤口痊愈,建立人体的抗体以防止细菌感染,治疗手术后的颤抖,防止疲劳。
棕榈酸视黄酯(维生素A棕榈酸酯)在本发明营养食品组合物中的主要作用是抗氧化、增强免疫力和保护心脑血管。
硝酸硫胺素(维生素B1硝酸盐)在本发明营养食品组合物中的主要作用是维持免疫功能,保持身体及精神系统正常工作,维持体内钠,钾成份平衡,制造红血球。
核黄素-5'-磷酸钠(核黄素-5'-(二氢磷酸酯)单钠盐)在本发明营养食品组合物中的主要作用是参与体内多种代谢和能量产生过程,对维护肌肉和神经系统的功能有重要作用。
5'-磷酸吡哆醛是一种具有3-羟基-2-甲基-5-[(膦酰氧基)甲基]-4-吡啶甲醛一水合物化学式的化合物,它在本发明营养食品组合物中的主要作用是参与氨基酸与脂肪酸代谢,是亚麻油酸转化成花生油酸的必需因子。
蝶酰谷氨酸(叶酸,维生素B9)在本发明营养食品组合物中的主要作用是参与血红蛋白及甲基化合物如肾上腺素、胆碱、肌酸等的合成,并对蛋白质、核酸的合成及各种氨基酸的代谢有重要作用。
盐酸氰钴胺是一种含有3价钴的多环系化学结构的化合物,它在本发明营养食品组合物中的主要作用是作为甲基转移酶的辅因子,参与蛋氨酸、胸腺嘧啶等的合成,促进蛋白质的生物合成。
D-生物素(维生素H)在本发明营养食品组合物中的主要作用是协助细胞生长、制造脂肪酸、代谢醣类、脂肪及蛋白质,且有助于B族维生素的利用,提高人体的免疫功能。
胆钙化醇(维生素D3)在本发明营养食品组合物中的主要作用是调节人体内的钙平衡,促进钙和磷的吸收代谢,保持骨骼健康;防治自身免疫性疾病、高血压和感染性疾病等。
植物甲萘醌是一种具有2-甲基-3-(3,7,11,15-四甲基十六-2-烯基)-1,4-萘醌化学式的化合物,它在本发明营养食品组合物中的主要作用是防止血管硬化等心血管疾病的发生。
甜菊糖苷(甜菊糖甙)在本发明营养食品组合物中的主要作用是作为甜味剂,优化产品口感,使患者在感官上对产品的接受度更高,提高顺应性。
本发明使用的微囊化花生油、微囊化橄榄油和微囊化番茄籽油的单不饱和脂肪酸和多不饱和脂肪酸比例较高,适合肥胖症患者长期食用。具有以下优点:
①保持细胞膜的相对流动性,以保正细胞的正常生理功能。
②使胆固醇酯化,降低血中胆固醇和甘油三酯。
③合成人体内前列腺素和凝血恶烷的前躯物质。
④降低血液粘稠度,改善血液微循环。
⑤提高脑细胞的活性,增强记忆力和思维能力。
⑥大部分脂肪储存在人体的脂肪细胞中,也有小部分储存在于血浆等其他人体细胞中。
⑦脂肪能够保护人体,减轻外界因素对重要器官的冲击,并可转化为能量。
⑧脂肪有益于新细胞的形成,并对维持正常的大脑发育和神经功能有着至关重要的作用。
⑨脂肪还是运载和帮助吸收脂溶性维生素所必需的物质,例如维生素A、D、E、K以及类胡萝卜素。
在本发明营养食品组合物中,葡萄糖酸钾、柠檬酸钠、硫酸镁、烟酸、甘氨酸亚铁、氧化锌、柠檬酸铜、碘化钾、钼酸铵、亚硒酸钠、氯化锰、牛奶蛋白、脱脂乳粉、豌豆蛋白、青稞粉等都是目前市场上销售的产品。
为维持正氮平衡及各组织器官功能正常代谢,应保证摄入足够的蛋白质,本发明蛋白质由牛奶蛋白、脱脂乳粉、豌豆蛋白组成,均为优质蛋白质来源;脱脂乳粉蛋白质含量丰富,脂肪含量低,适宜肥胖人群食用;牛奶蛋白为动物蛋白,豌豆蛋白为不含胆固醇的全价蛋白质,动物来源和植物来源蛋白添加比例为1:1,可达到蛋白质的互补,提高蛋白质的营养价值。
青稞粉添加可使摄入的热能减少,在肠道内营养的消化吸收也下降,最终使体内脂肪消耗而起减肥作用。可以使人产生轻微的饱腹感,减少过多热量的吸收,又可以包覆多余糖分和油脂随同肠道内的老旧沉积废物一同排出体外。
青稞是一种很重要的高原谷类作物,具有早熟、耐寒、耐痔薄、稳产和适应性广等特点,青稞具有高蛋白质、高纤维、高维生素、低脂肪、低糖等特点。其蛋白质含量为6.35%-21.0%,平均值为11.31%,高于小麦、水稻、玉米。粗脂肪为1.18%-3.09%,平均值为2.13%,比玉米和燕麦低,但高于小麦和水稻。它还含降胆固醇作用的油酸、亚油酸、亚麻酸、α-生育酚、卵磷脂、脑磷脂等。可溶性纤维和总纤维含量均高于其它谷类作物。青稞富含B族维生素、维生素C等,是B族维生素极好来源;所含微量元素钙、磷、铁、铜、锌、锰、硒都高于玉米,其中,铁的含量高于小麦、水稻。西藏青棵β-葡聚糖含量在3.66%-8.62%之间,平均值为5.25%,是迄今为止测得在谷类作物中最高值,远远高于皮大麦、小麦和燕麦,而近年来研究发现,青稞β-葡聚糖具有抗癌、降血脂、降血糖等功效。
优选地,所述的营养食品组合物组成如下:以重量份计
牛奶蛋白3.34~3.46份;脱脂乳粉2.56~2.70份;豌豆蛋白3.02~3.22份;青稞粉1.94~2.06份;水解玉米淀粉5.96~6.04份;膳食纤维3.60~3.80份;微囊化花生油0.54~0.60份;微囊化橄榄油0.53~0.62份;微囊化番茄籽油0.14~0.22份;HMB-Ca 0.24~0.26份;食品用香精0.18~0.22份;葡萄糖酸钙0.16~0.20份;甜菊糖苷0.11~0.13份;葡萄糖酸钾0.10~0.12份;柠檬酸钠0.09~0.11份;硫酸镁0.075~0.085份;L-抗坏血酸-6-棕榈酸盐(3.2~3.4)×10-2份;dl-α-琥珀酸生育酚(3.5~3.7)×10-3份;烟酸(8.3~8.5)×10-3份;D-泛酸钙(2.4~2.6)×10-3份;甘氨酸亚铁(4.4~4.6)×10-3份;氧化锌(2.7~2.9)×10-3份;棕榈酸视黄酯(3.0~3.2)×10-4份;柠檬酸铜(3.8~4.0)×10-4份;硝酸硫胺素(8.3~8.5)×10-4份;核黄素-5'-磷酸钠(5.5~5.7)×10-4份;5'-磷酸吡哆醛(5.5~5.7)×10-4份;蝶酰谷氨酸(0.9~1.1)×10-4份;碘化钾(6.1~6.3)×10-5份;钼酸铵(1.3~1.5)×10-5份;亚硒酸钠(1.15~1.35)×10-5份;盐酸氰钴胺(1.70~1.9)×10-6份;D-生物素(3.9~4.1)×10-6份;氯化锰(1.1~1.3)×10-6份;胆钙化醇(2.0~2.2)×10-6份;植物甲萘醌(4.0~6.0)×10-6份。
更优选地,所述的营养食品组合物组成如下:以重量份计
牛奶蛋白3.40份;脱脂乳粉2.62份;豌豆蛋白3.12份;青稞粉2.0份;水解玉米淀粉6.0份;膳食纤维3.70份;微囊化花生油0.57份;微囊化橄榄油0.58份;微囊化番茄籽油0.18份;HMB-Ca 0.22份;食品用香精0.20份;葡萄糖酸钙0.18份;甜菊糖苷0.12份;葡萄糖酸钾0.11份;柠檬酸钠0.10份;硫酸镁0.08份;L-抗坏血酸-6-棕榈酸盐3.3×10-2份;dl-α-琥珀酸生育酚3.6×10-3份;烟酸8.4×10-3份;D-泛酸钙2.5×10-3份;甘氨酸亚铁4.5×10-3份;氧化锌2.8×10-3份;棕榈酸视黄酯3.1×10-4份;柠檬酸铜3.9×10-4份;硝酸硫胺素8.4×10-4份;核黄素-5'-磷酸钠5.6×10-4份;5'-磷酸吡哆醛5.6×10-4份;蝶酰谷氨酸1.0×10-4份;碘化钾6.2×10-5份;钼酸铵1.4×10-5份;亚硒酸钠1.25×10-5份;盐酸氰钴胺1.8×10-6份;D-生物素4.0×10-6份;氯化锰1.2×10-6份;胆钙化醇2.1×10-6份;植物甲萘醌5.0×10-6份。
本发明营养食品组合物制备方法如下:将上述组分按照其含量采用三维混合机充分混合均匀,就得到用于肥胖、减脂手术患者食用的全营养配方食品。
本发明营养食品组合物食用方法如下:用200mL温开水(45~50℃)冲调均匀即可食用。
[有益效果]
本发明的有益效果是:本发明的全营养配方食品含有丰富的维生素、矿物质及微量元素,能有效保证维生素和矿物质的供应,弥补肥胖营养治疗时,由于长期限制饮食导致的维生素和矿物质的缺乏。本发明营养食品组合物具有血脂、体重指数等指标明显改善作用,且青稞粉和HMB-Ca具有显著的协同效果,因此,本发明营养食品组合物在肥胖或减脂手术患者中具有非常好的应用前景。
【具体实施方式】
通过下述实施例将能够更好地理解本发明。
实施例1:本发明营养食品组合物制备
该实施例的实施方式如下:
称取以重量份计3.30份牛奶蛋白、2.63份脱脂乳粉、3.08份豌豆蛋白、2.0份青稞粉、5.90份水解玉米淀粉、3.65份膳食纤维、0.55份微囊化花生油、0.60份微囊化橄榄油、0.16份微囊化番茄籽油、0.22份HMB-Ca、0.16份食品用香精、0.18份葡萄糖酸钙、0.11份甜菊糖苷、0.10份葡萄糖酸钾、0.09份柠檬酸钠、0.080份硫酸镁、3.2×10-2份L-抗坏血酸-6-棕榈酸盐、3.5×10-3份dl-α-琥珀酸生育酚、8.4×10-3份烟酸、2.4×10-3份D-泛酸钙、4.4×10-3份甘氨酸亚铁、2.7×10-3份氧化锌、3.0×10-4份棕榈酸视黄酯、3.8×10-4份柠檬酸铜、8.4×10-4份硝酸硫胺素、5.6×10-4份核黄素-5'-磷酸钠、5.6×10-4份5'-磷酸吡哆醛、0.9×10-4份蝶酰谷氨酸、6.1×10-5份碘化钾、1.3×10-5份钼酸铵、1.25×10-5份亚硒酸钠、1.80×10-6份盐酸氰钴胺、3.9×10-6份D-生物素、1.1×10-6份氯化锰、2.0×10-6份胆钙化醇、4.0×10-6份植物甲萘醌;
将上述组分按照其量采用三维混合机充分混合均匀,得到本发明用于肥胖或减脂手术患者食用的营养食品组合物。
实施例2:本发明营养食品组合物制备
该实施例的实施方式如下:
称取以重量份计3.50份牛奶蛋白、2.53份脱脂乳粉、3.18份豌豆蛋白、1.90份青稞粉、6.0份水解玉米淀粉、3.85份膳食纤维、0.60份微囊化花生油、0.55份微囊化橄榄油、0.20份微囊化番茄籽油、0.28份HMB-Ca、0.20份食品用香精、0.16份葡萄糖酸钙、0.12份甜菊糖苷、0.12份葡萄糖酸钾、0.10份柠檬酸钠、0.075份硫酸镁、3.3×10-2份L-抗坏血酸-6-棕榈酸盐、3.7×10-3份dl-α-琥珀酸生育酚、8.3×10-3份烟酸、2.6×10-3份D-泛酸钙、4.5×10-3份甘氨酸亚铁、2.9×10-3份氧化锌、3.2×10-4份棕榈酸视黄酯、3.9×10-4份柠檬酸铜、8.3×10-4份硝酸硫胺素、5.5×10-4份核黄素-5'-磷酸钠、5.6×10-4份5'-磷酸吡哆醛、1.1×10-4份蝶酰谷氨酸、6.3×10-5份碘化钾、1.4×10-5份钼酸铵、1.15×10-5份亚硒酸钠、1.70×10-6份盐酸氰钴胺、4.0×10-6份D-生物素、1.3×10-6份氯化锰、2.2×10-6份胆钙化醇、5.0×10-6份植物甲萘醌。
将上述组分按照其量采用三维混合机充分混合均匀,得到本发明用于肥胖或减脂手术患者食用的营养食品组合物。
实施例3:本发明营养食品组合物制备
该实施例的实施方式如下:
称取以重量份计3.40份牛奶蛋白、2.73份脱脂乳粉、3.28份豌豆蛋白、2.10份青稞粉、6.10份水解玉米淀粉、3.75份膳食纤维、0.65份微囊化花生油、0.65份微囊化橄榄油、0.24份微囊化番茄籽油、0.25份HMB-Ca、0.24份食品用香精、0.20份葡萄糖酸钙、0.13份甜菊糖苷、0.11份葡萄糖酸钾、0.11份柠檬酸钠、0.085份硫酸镁、3.4×10-2份L-抗坏血酸-6-棕榈酸盐、3.6×10-3份dl-α-琥珀酸生育酚、8.5×10-3份烟酸、2.5×10-3份D-泛酸钙、4.6×10-3份甘氨酸亚铁、2.8×10-3份氧化锌、3.1×10-4份棕榈酸视黄酯、4.0×10-4份柠檬酸铜、8.5×10-4份硝酸硫胺素、5.7×10-4份核黄素-5'-磷酸钠、5.7×10-4份5'-磷酸吡哆醛、1.0×10-4份蝶酰谷氨酸、6.2×10-5份碘化钾、1.5×10-5份钼酸铵、1.35×10-5份亚硒酸钠、1.9×10-6份盐酸氰钴胺、4.1×10-6份D-生物素、1.2×10-6份氯化锰、2.1×10-6份胆钙化醇、6.0×10-6份植物甲萘醌。
将上述组分按照其量采用三维混合机充分混合均匀,得到本发明用于肥胖或减脂手术患者食用的营养食品组合物。
试验实施例1
为了解本发明用于肥胖或减脂手术患者的营养食品组合物对人体血脂、体重的影响,观察了426名肥胖症患者服用产品前后血脂、体重指数的改变。同时考察青稞粉和HMB-Ca对大鼠减肥降脂的效果,并比较了两种营养物质在配方中单独使用和联用时的协同效果。
该试验实施例的实施方式如下:
I、试验时间:2015年6月至2016年4月。
II、试验样品:
1#受试品:实施例1制备的本发明用于肥胖、减脂手术营养食品组合物:食用时取4-5量匙,约48g,用约200mL温开水调匀食用。
2#受试品:将1#受试品配方中青稞粉替换为等质量的麦芽糊精,其余成分含量不变,食用方法不变。
3#受试品:将1#受试品配方中HMB-Ca替换为等质量的麦芽糊精,其余成分含量不变,食用方法不变。
III、试验人员:
以本市城市社区肥胖症患者为研究对象,按照下述纳入、排除标准从中选取符合条件的患者426例,采用随机数字表法将纳入的所有患者分为研究组和对照组。
纳入标准:(1)在本市社区卫生服务站建立过居民健康档案;(2)长期固定居住于本辖区的居民;(3)肥胖症患者;(4)愿意配合且易随访者。
排除标准:(1)孕妇、哺乳妇女;(2)服用荷尔蒙以及降胆固醇药物者;(3)需要胰岛素治疗者;(4)有语言沟通障碍或身体活动不方便者;(5)有其他较为严重的并发症者。
研究组患者共318例,其中男121例,女115例;年龄30~67岁,平均年龄53.6岁;病程小于5年的患者108例,5~10年88例,10~20年34例,≥20年6例。采用随机数字表法将研究组又分为3组,每组106人,分别记为A组、B组和C组。
空白对照组患者108例,其中男56例,女52例;年龄30~67岁,平均年龄54.1岁;病程小于5年的患者39例,5~10年32例,10~20年27例,≥20年10例。记为D组。
上述几组患者性别、年龄和病程等一般资料,差异无统计学意义(P>0.05),具可比性。
III、试验方法
D组给予肥胖症患者的常规护理,包括饮食、运动和用药指导;A组、B组、C组给予常规护理外,每日分别对应增加1#受试品、2#受试品、3#受试品作为营养干预。
在接受试验前,A组、B组、C组和D组所有受试人员都需进行甘油三脂(TG)、总胆固醇(TC,采用酶法测定)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C,采用匀相法测定)和体重指数(BMI)的检测和记录。监测跟踪每日受试人员的食用情况,食用周期为60天,对以上指标进行再次检测。
IV、试验结果
采用SPSS统计学软件进行数据处理和统计学分析;数据以表示,组间比较采用t检验;以ɑ=0.05为检验水准,p<0.05为差异有统计学意义。
(1)血脂检测项目结果
表1:四组受试人员血脂指标比较(p<0.05)
由表1可知,四组肥胖症患者干预前后,同对照组(D组)相比,A组、B组和C组能够显著降低TG、TC和LDL-C水平值(p<0.05),且A组效果显著优于B组和C组。而4组受试组HDL-C水平值干预后均高于干预前,干预前后各项指标组内比较差异均有统计学意义(p<0.05)。
(2)BMI指标
表2:WHO关于体重指数的界定表
表3:四组受试人员BMI指标比较(p<0.05)
由以上数据可以看出,四组肥胖症患者干预前后,研究组(A组、B组、C组)和对照组(D组)BMI指标变化显著,通过表2数据知道,研究组(A组、B组、C组)由1级肥胖降低为超重程度,研究组较对照组改善更明显,且A组效果优于B组和C组,采用本发明配方营养干预后BMI指标组间比较差异有统计学意义(p<0.05)。
由此可见,研究组(A组、B组和C组)较对照组(D组)血脂、体重指数指标改善更明显,且研究组中A组最佳,即配方中青稞粉和HMB-Ca的协同效果显著高于两种营养物质在配方中单独使用,采用本发明配方营养干预后各项血脂指标组间比较差异有统计学意义(<0.05)。
Claims (2)
1.一种用于肥胖或减脂手术患者的营养食品组合物,其特征在于该营养食品组合物组成如下:以重量份计
牛奶蛋白3.30~3.50份;脱脂乳粉2.53~2.73份;豌豆蛋白3.08~3.28份;青稞粉1.90~2.10份;水解玉米淀粉5.90~6.10份;膳食纤维3.65~3.85份;微囊化花生油0.55~0.65份;微囊化橄榄油0.55~0.65份;微囊化番茄籽油0.16~0.24份;HMB-Ca 0.22~0.28份;食品用香精0.16~0.24份;葡萄糖酸钙0.16~0.20份;甜菊糖苷0.11~0.13份;葡萄糖酸钾0.10~0.12份;柠檬酸钠0.09~0.11份;硫酸镁0.075~0.085份;L-抗坏血酸-6-棕榈酸盐(3.2~3.4)×10-2份;dl-α-琥珀酸生育酚(3.5~3.7)×10-3份;烟酸(8.3~8.5)×10-3份;D-泛酸钙(2.4~2.6)×10-3份;甘氨酸亚铁(4.4~4.6)×10-3份;氧化锌(2.7~2.9)×10-3份;棕榈酸视黄酯(3.0~3.2)×10-4份;柠檬酸铜(3.8~4.0)×10-4份;硝酸硫胺素(8.3~8.5)×10-4份;核黄素-5'-磷酸钠(5.5~5.7)×10-4份;5'-磷酸吡哆醛(5.5~5.7)×10-4份;蝶酰谷氨酸(0.9~1.1)×10-4份;碘化钾(6.1~6.3)×10-5份;钼酸铵(1.3~1.5)×10-5份;亚硒酸钠(1.15~1.35)×10-5份;盐酸氰钴胺(1.70~1.9)×10-6份;D-生物素(3.9~4.1)×10-6份;氯化锰(1.1~1.3)×10-6份;胆钙化醇(2.0~2.2)×10-6份;植物甲萘醌(4.0~6.0)×10-6份。
2.根据权利要求1所述的营养食品组合物,其特征在于该营养食品组合物组成如下:以重量份计
牛奶蛋白3.34~3.46份;脱脂乳粉2.56~2.70份;豌豆蛋白3.02~3.22份;青稞粉1.94~2.06份;水解玉米淀粉5.96~6.04份;膳食纤维3.60~3.80份;微囊化花生油0.54~0.60份;微囊化橄榄油0.53~0.62份;微囊化番茄籽油0.14~0.22份;HMB-Ca 0.24~0.26份;食品用香精0.18~0.22份;葡萄糖酸钙0.16~0.20份;甜菊糖苷0.11~0.13份;葡萄糖酸钾0.10~0.12份;柠檬酸钠0.09~0.11份;硫酸镁0.075~0.085份;L-抗坏血酸-6-棕榈酸盐(3.2~3.4)×10-2份;dl-α-琥珀酸生育酚(3.5~3.7)×10-3份;烟酸(8.3~8.5)×10-3份;D-泛酸钙(2.4~2.6)×10-3份;甘氨酸亚铁(4.4~4.6)×10-3份;氧化锌(2.7~2.9)×10-3份;棕榈酸视黄酯(3.0~3.2)×10-4份;柠檬酸铜(3.8~4.0)×10-4份;硝酸硫胺素(8.3~8.5)×10-4份;核黄素-5'-磷酸钠(5.5~5.7)×10-4份;5'-磷酸吡哆醛(5.5~5.7)×10-4份;蝶酰谷氨酸(0.9~1.1)×10-4份;碘化钾(6.1~6.3)×10-5份;钼酸铵(1.3~1.5)×10-5份;亚硒酸钠(1.15~1.35)×10-5份;盐酸氰钴胺(1.70~1.9)×10-6份;D-生物素(3.9~4.1)×10-6份;氯化锰(1.1~1.3)×10-6份;胆钙化醇(2.0~2.2)×10-6份;植物甲萘醌(4.0~6.0)×10-6份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610965457.5A CN106360742A (zh) | 2016-11-04 | 2016-11-04 | 一种用于肥胖或减脂手术患者的营养食品组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610965457.5A CN106360742A (zh) | 2016-11-04 | 2016-11-04 | 一种用于肥胖或减脂手术患者的营养食品组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106360742A true CN106360742A (zh) | 2017-02-01 |
Family
ID=57894063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610965457.5A Pending CN106360742A (zh) | 2016-11-04 | 2016-11-04 | 一种用于肥胖或减脂手术患者的营养食品组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106360742A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107173794A (zh) * | 2017-06-12 | 2017-09-19 | 金梅 | 一种促进重症颅脑损伤患者恢复的营养组合物及其应用 |
CN109090615A (zh) * | 2018-09-29 | 2018-12-28 | 哈尔滨快好药业有限公司 | 一种用于补充维生素d及多种矿物质的保健食品及其制备方法和应用 |
CN110403014A (zh) * | 2019-07-24 | 2019-11-05 | 海普诺凯营养品有限公司 | 一种能抑制食欲的营养粉及其制备方法与应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102783610A (zh) * | 2012-08-22 | 2012-11-21 | 杭州诺伽特健康科技有限公司 | 一种代餐谷物棒及其制备方法 |
CN103416760A (zh) * | 2013-08-28 | 2013-12-04 | 山东卫康生物医药科技有限公司 | 治疗和预防肌肉衰减综合症的五谷杂粮全营养配方食品 |
AU2012204109A1 (en) * | 2012-07-12 | 2014-01-30 | Xinyue Xu | Nutritional composition and method of making |
CN105685970A (zh) * | 2016-02-01 | 2016-06-22 | 北京东方兴企食品工业技术有限公司 | 一种全消化道改善的复合营养食品 |
-
2016
- 2016-11-04 CN CN201610965457.5A patent/CN106360742A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012204109A1 (en) * | 2012-07-12 | 2014-01-30 | Xinyue Xu | Nutritional composition and method of making |
CN102783610A (zh) * | 2012-08-22 | 2012-11-21 | 杭州诺伽特健康科技有限公司 | 一种代餐谷物棒及其制备方法 |
CN103416760A (zh) * | 2013-08-28 | 2013-12-04 | 山东卫康生物医药科技有限公司 | 治疗和预防肌肉衰减综合症的五谷杂粮全营养配方食品 |
CN105685970A (zh) * | 2016-02-01 | 2016-06-22 | 北京东方兴企食品工业技术有限公司 | 一种全消化道改善的复合营养食品 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107173794A (zh) * | 2017-06-12 | 2017-09-19 | 金梅 | 一种促进重症颅脑损伤患者恢复的营养组合物及其应用 |
CN109090615A (zh) * | 2018-09-29 | 2018-12-28 | 哈尔滨快好药业有限公司 | 一种用于补充维生素d及多种矿物质的保健食品及其制备方法和应用 |
CN110403014A (zh) * | 2019-07-24 | 2019-11-05 | 海普诺凯营养品有限公司 | 一种能抑制食欲的营养粉及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Trinidad et al. | Dietary fiber from coconut flour: A functional food | |
CN110326782A (zh) | 一种具有减肥功效的营养代餐及其制备方法 | |
CN111528483A (zh) | 一种均衡营养的功能代餐粉及其制备方法 | |
US8927033B2 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and food or beverage | |
CN103238897A (zh) | 一种适用于糖尿病人的复合植物固体饮料 | |
CN102366093A (zh) | 一种复合减肥保健食品 | |
CN110810845A (zh) | 一种具有生酮、减脂、抗糖功能的全营养配方粉及其应用 | |
CN109077124A (zh) | 一种生酮饮食减肥组合物及其应用 | |
CN106605744A (zh) | 一种具有降脂瘦身排毒养颜的组合物及其制备方法 | |
US8663679B2 (en) | Compositions for improving breast health in women | |
CN103141741A (zh) | 一种含有丰富膳食纤维的食品添加原料及其应用 | |
CN103689375A (zh) | 一种适合糖尿病人的面条配方及其加工方法 | |
CN113017089A (zh) | 提高基础代谢水平的代餐组合物及制备方法和应用 | |
CN106360742A (zh) | 一种用于肥胖或减脂手术患者的营养食品组合物 | |
CN110101088A (zh) | 用于妊娠糖尿病防治的精准营养代餐组合物及其使用方法 | |
CN103191092B (zh) | 一种具有补钙和补锌作用的药物组合物 | |
CN105031042A (zh) | 一种具有减肥功能的药物组合物及其应用 | |
KR101896024B1 (ko) | 가르시니아 캄보지아 추출물을 활용한 기능성 식품 조성물 및 이의 제조방법 | |
CA2564592C (en) | Compositions for improving breast health in women | |
CN109090580A (zh) | 一种用于肿瘤患者的特定全营养配方食品及其制备方法 | |
CN111213690A (zh) | 一种低gi鹰嘴豆淀粉面包的配方及其制备方法 | |
CN107223981B (zh) | 含大豆多肽阿格拉欣的组合物及其制备方法 | |
CN105433382B (zh) | 一种玛咖组合物及其制备方法和用途 | |
MX2008015252A (es) | Composiciones supresoras del apetito de porcion unitaria con glicosidos esteroidales. | |
CN106858578A (zh) | 适于糖尿病患者食用的营养面粉 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |
|
RJ01 | Rejection of invention patent application after publication |